Trial Profile
Phase II Trial of Temodar [temozolomide] Plus O6-Benzylguanine [benzylguanine] (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Benzylguanine (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioma
- Focus Therapeutic Use
- 29 Jan 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 22 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2008 New trial record.